Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Status:
RECRUITING
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
In mCRC, response to second-line chemotherapy is limited, and few treatment options are available. It is urgent to design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients with mCRC. Several studies preliminarily demonstrated that irinotecan, TAS-102 plus bevacizumab regimen could bring promising efficacy with a tolerable safety profile for patients with mCRC as a second-line treatment. This phase I/II study was aimed to determine the recommended phase II dose (RP2D) of the combination of TAS-102, irinotecan, and bevacizumab for future clinical trials in patients with mCRC refractory to both fluoropyrimidine and oxaliplatin and to evaluate its safety and preliminary efficacy.
Phase:
PHASE1
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
Irinotecan tipiracil Trifluridine trifluridine tipiracil drug combination